Biotechs crow about getting special treatment at FDA — but our data show investors don’t give them much credit.
When Biotechs Get Breakthrough Therapy Status, Mr. Market Yawns
Biotechs crow about getting special treatment at FDA — but our data show investors don’t give them much credit.